Levifix 500 Tablet contains Levetiracetam 500mg, an antiepileptic medication indicated for the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby stabilizing neuronal activity and reducing seizure frequency. Levifix 500 is prescribed as adjunctive therapy or monotherapy depending on the clinical scenario and patient response. The tablet should be administered orally, with dosage adjustments individualized based on patient age, renal function, and therapeutic response. Common adverse effects include somnolence, dizziness, headache, and fatigue, which are generally mild to moderate and transient. Serious side effects are rare but may include behavioral changes, mood alterations, and hypersensitivity reactions, necessitating close monitoring during treatment initiation and dose escalation. Caution is advised in patients with renal impairment, and dose modification is recommended accordingly. Levifix 500 does not induce hepatic enzymes significantly, reducing the risk of drug interactions. It is contraindicated in patients with known hypersensitivity to Levetiracetam or any excipients. Regular follow-up and adherence to prescribed dosing are essential to optimize therapeutic outcomes and minimize adverse effects.